New analysis of LIFE trial shows reduction of new-onset atrial fibrillation with losartan

Br J Cardiol 2005;12:268-9 Leave a comment
Click any image to enlarge
Authors:

A new analysis of the LIFE study has shown that losartan can reduce new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. General practitioner Brian Crichton summarises this new analysis and explains how losartan might achieve these effects.








Advertisement

For UK healthcare professionals only


THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT